Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.3%

1 terminated/withdrawn out of 76 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

11%

8 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

N/A
31(67.4%)
Phase 2
4(8.7%)
Phase 3
4(8.7%)
Phase 4
4(8.7%)
Early Phase 1
2(4.3%)
Phase 1
1(2.2%)
46Total
N/A(31)
Phase 2(4)
Phase 3(4)
Phase 4(4)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (76)

Showing 20 of 76 trials
NCT07426146Recruiting

Feasibility Effects of a Low-GI, High-fibre Diet in PCOS: a Prospective Cohort Study in Remote Yunnan

Role: lead

NCT07269574Not Yet Recruiting

Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance

Role: collaborator

NCT07202728Recruiting

A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)

Role: collaborator

NCT07161947Recruiting

Shanghai Clinical Cohort of Hyperglycemia in Pregnancy

Role: collaborator

NCT07002346Phase 3Not Yet Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT05179447Not ApplicableRecruiting

PROfiling Based Endometrial Cancer Adjuvant Therapy

Role: collaborator

NCT06847386Not ApplicableEnrolling By Invitation

Effect of Hysteroscopic Metroplasty on Reproductive Outcome in Patients with RIF

Role: lead

NCT06666933Not ApplicableEnrolling By Invitation

Study of Time-restricted Eating (TRE) to Clinical Pregnancy Rate in PCOS Women With Glucose Metabolism Disorder Via IVF/ICSI

Role: collaborator

NCT04733937Not ApplicableCompleted

Comparative Effects of A2 Platinum Stage 1 Infant Formula on Infant Digestion and Comfort

Role: collaborator

NCT05594095Phase 2Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Role: collaborator

NCT06612814Phase 3Active Not Recruiting

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Role: collaborator

NCT06104748Recruiting

A Cohort of Maternal Vascular Malperfusion-related FGR (CoMVMFGR)

Role: lead

NCT06096805Recruiting

Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

Role: lead

NCT06414655Recruiting

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China

Role: collaborator

NCT04989348Not ApplicableCompleted

Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol

Role: lead

NCT05205200Phase 2Recruiting

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Role: collaborator

NCT05759546Phase 2Recruiting

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Role: collaborator

NCT05759572Phase 2Recruiting

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Role: collaborator

NCT04531839Not ApplicableWithdrawn

Improving Outcome of Very Preterm Infants Using Collaborative Quality Improvement

Role: collaborator

NCT05580523Not ApplicableUnknown

Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial

Role: collaborator